Funder
Natural Science Foundation of Heilongjiang Province
Heilongjiang Provincial Postdoctoral Science Foundation
Harbin Medical University
China Postdoctoral Science Foundation
National Natural Science Foundation of China
Subject
Industrial and Manufacturing Engineering,General Chemical Engineering,Environmental Chemistry,General Chemistry
Reference50 articles.
1. Cancer statistics, 2021;Siegel;CA Cancer J. Clin.,2021
2. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC;Wang;Signal Transduct. Target Ther,2020
3. Pancreatic cancer;Vincent;Lancet,2011
4. Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer;Nakano;BMJ Open,2022
5. U. Groupe Tumeurs Digestives of, P. Intergroup, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N. Engl. J. Med.,2011
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献